Q3 EBIT was comfortably ahead of SEB expectations, as management continued to execute strong cost control. Clear progress is being made on the partnering, clinical, and organisational fronts, and there is now regulatory clarity on the high-grade glioma path to approval. Following estimate revisions to reflect potential new equity on the back of expected positive ph2 data in 2027, we revise our valuation range to SEK 101-117 (147-159).
LÄS MER
